What You Need to Know About High / Very High LDL Cholesterol Levels
Many factors can influence cholesterol and triglyceride levels. Individuals with high LDL cholesterol values should be evaluated for potential secondary causes, including hypothyroidism, diabetes, liver disease, chronic kidney disease, and medications such as estrogens, progestins, anabolic steroids/androgens, corticosteroids, cyclosporine, retinoids, certain antipsychotic medications, and antiretrovirals (particularly protease inhibitors).1
Additionally, genetic abnormalities can cause significant cholesterol elevations. More commonly, several genes cluster together to increase LDL-C. This is called “polygenic” high cholesterol.2
In many cases, a single dominant gene runs in families and causes very high LDL-C levels from birth. This is known as familial hypercholesterolemia, or “FH”.
FH is a common, life-threatening genetic disorder present in 1 in 250 people of all races and ethnicities.3
If one parent carries an FH gene, each child born has a 50% chance of inheriting FH.
Because FH causes high LDL levels from birth, people with FH have a 5-7 fold higher risk of heart attack versus someone without FH at the same LDL level.4
If left untreated, men have a 50% risk of having a heart attack by age 50. Untreated women have a 30% risk of having a heart attack by age 60.4,5
FH related cardiovascular risk can be reduced.6 When LDL is lowered and maintainedat appropriate levels, FH patients have significantly less cardiovascular risk over time.
Most commonly, FH is diagnosed clinically using a validated scoring system based on the following factors in the patient and close relatives (mother, father, siblings, and children).4
LDL-C levels > 190 mg/dL in adults or > 160 mg/dL in children < 18 years of age
History of premature vascular disease (men < 55 years old, women < 65 years old)
Selected physical manifestations including:
Presence of Achilles tendon thickening,
- Xanthomas (cholesterol deposits in skin or tendons), or
- Corneal Arcus (white ring around the colored part of the eye before the age of 45)
- Confirmatory genetic testing (if available)
Scoring systems used identify FH include the Dutch Lipid Clinic Network (DLCN) score, the Simone-Broom score, and the American Heart Association score.
Overall, the more criteria present, the greater the clinical likelihood of FH.7
The DLCN score classifies an individual’s likelihood of FH as follows:7
Definite FH: >8 Points
Probable FH: 6 to 7 Points
Possible FH: 3 to 5 Points
Unlikely FH: < 3 Points
- For more information visit The FH Foundation.
Conclusion & Your Next Steps
High cardiovascular risk trends with high LDL. The higher the LDL for a longer time, increases your risk. The lower the LDL for a longer time, decreases your risk. Here are actions you can take under the care of a licensed physician in your area:
If your LDL-C is greater than 190 or your non-HDL-C is greater than 210, you should consult with a knowledgeable physician to attempt to rule out the presence of familial hypercholesterolemia.
If after 6 months of good diet and lifestyle change, your LDL-C is greater than 130 or your non-HDL-C is greater than 160, you should seek consultation with a knowledgable physician to discuss bringing these values down into a normal range.
References
The Washington Manual of Medical Therapeutics, 36th Edition.
Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2020.
Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. BMJ Open 2017; 7:e016461.
Knowles JW, O'Brien EC, Greendale K, et al. Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. Am Heart J 2014; 168:807-11.
Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis 2003; 168:1-14.
Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. BMJ 2008; 337:a2423.
Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S9-17.